Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03224507 · ClinicalTrials.gov registry record · Phase 2
Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma
A Phase 2 study of Multiple Myeloma, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 123
- Enrollment target
- 4
- Study locations
NCT03224507 is a Phase 2 study of Multiple Myeloma that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 123 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (77% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT03224507, a Phase 2 study of Multiple Myeloma, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 123 participants
- Enrollment target
- 4
- Study locations
Study Summary
Multiple myeloma (MM), a plasma cell disorder, is the second most common hematologic malignancy in the U.S. No standard curative therapy has yet been found. A variety of therapeutic measures including high dose melphalan, induction therapy, and continuous therapy have been used but the goal of complete response without relapse has not been achieved. More active treatment regimens and better tools for response assessment are needed.
Conditions Studied
Interventions
- DRUG KRdD followed by auto-HCT
- DRUG KRdD only
Study Locations (4)
Alabama
- University of Alabama at Birmingham - Birmingham
Oregon
- Oregon Health and Science University - Portland
Tennessee
- Vanderbilt Ingram Cancer Center - Nashville
Wisconsin
- University of Wisconsin, school of medicine and public health - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2018-03-14 |
| Est. Completion | 2023-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03224507
The ClinicalTrials.gov registry entry for NCT03224507 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (77% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which KRdD followed by auto-HCT is the first listed.
NCT03224507 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Alabama, Oregon, Tennessee.
Frequently Asked Questions
What is clinical trial NCT03224507 about?
NCT03224507 is a clinical study titled "Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma". Multiple myeloma (MM), a plasma cell disorder, is the second most common hematologic malignancy in the U.S. No standard curative therapy has yet been found. A variety of therapeutic measures including high dose melphalan, induction therapy, and continuous therapy have been used but the goal of compl...
What is the current status of trial NCT03224507?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 123 participants. The study started on 2018-03-14. Estimated completion is 2023-06-30.
What conditions does trial NCT03224507 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT03224507?
The interventions under investigation include: KRdD followed by auto-HCT (DRUG), KRdD only (DRUG).
Who is sponsoring clinical trial NCT03224507?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03224507 being conducted?
This trial has 4 study locations across Alabama, Oregon, Tennessee, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.